Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Waystar to $32 from $27 and keeps an Outperform rating on the shares. The firm is adjusting estimates and making additions to Evercore’s “Tactical Outperform” and “Tactical Underperform” lists ahead of Q3 earnings from the Healthcare Technology and Distribution group. The firm added Waystar to the “Tactical Outperform” list as it argues that ongoing tailwinds from Change disruptions and elevated utilization trends set the company up to perform well in its second quarter post-IPO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar price target raised to $31 from $27 at RBC Capital
- Waystar price target raised to $27 from $24 at JPMorgan
- Waystar price target raised to $31 from $27 at Deutsche Bank
- Waystar price target raised to $32 from $24 at Barclays